LentiArray™ CRISPR Positive Control Lentivirus, human HPRT
Product Image
引用和文献 (1)
Invitrogen™

LentiArray™ CRISPR Positive Control Lentivirus, human HPRT

Optimizing delivery conditions is a critical step in any experiment utilizing the CRISPR/Cas9 system. The Invitrogen™ LentiArray™ CRISPR Positive Control了解更多信息
Have Questions?
货号数量
A32056100 μL
货号 A32056
价格（CNY)
4,165.00
Each
添加至购物车
数量:
100 μL
价格（CNY)
4,165.00
Each
添加至购物车
Optimizing delivery conditions is a critical step in any experiment utilizing the CRISPR/Cas9 system. The Invitrogen™ LentiArray™ CRISPR Positive Control Lentivirus gRNA against HPRT is a highly efficient gRNA validated in multiple human cell lines that has achieved editing efficiencies of greater than 80%. It can be used to rapidly determine ideal delivery conditions in order to achieve maximum editing efficiency in your cell model of choice.
仅供科研使用。不可用于诊断程序。
规格
控制类型阳性对照
输送类型慢病毒
适用于（应用）CRISPR 基因敲除
产品线LentiArray
产品类型CRISPR 阳性对照慢病毒
数量100 μL
运输条件干冰
促进剂U6
种属人
转染技术慢病毒转导
Unit SizeEach
内容与储存
1 x 100 µL。储存（-68°C 至 -85°C）

引用和文献 (1)

引用和文献
Abstract
A functional screening of the kinome identifies the Polo-like kinase 4 as a potential therapeutic target for malignant rhabdoid tumors, and possibly, other embryonal tumors of the brain.
Authors:Sredni ST, Suzuki M, Yang JP, Topczewski J, Bailey AW, Gokirmak T, Gross JN, de Andrade A, Kondo A, Piper DR, Tomita T
Journal:Pediatr Blood Cancer
PubMed ID:28398638
Malignant rhabdoid tumors (MRTs) are deadly embryonal tumors of the infancy. With poor survival and modest response to available therapies, more effective and less toxic treatments are needed. We hypothesized that a systematic screening of the kinome will reveal kinases that drive rhabdoid tumors and can be targeted by specific ... More